Press Releases
Connect Biopharmaceuticals to Present at the 11th Biotech Showcase on January 7, 2019 during the 37th JP Morgan Healthcare Conference

Taicang, Suzhou, China, December. 15, 2018 - Connect Biopharmaceuticals, today announced that Dr. Zheng Wei, the company's co-founder and Chief Executive Officer, will present an update on the company’s clinical programs and drug discovery platform at the upcoming Biotech Showcase conference on Monday, January 7, 2019, at 9:15 am PST.  The conference will be held on January 7–9, 2019 at the Hilton San Francisco Union Square, San Francisco.


About Biotech Showcase

Biotech Showcase Investor Partnering Conference is co-produced by Demy-Colton Life Science Advisors and EBD Group. It is an investor and networking conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the JP Morgan Healthcare Conference that attracts investors and biopharmaceutical executives from around the world.


About Connect Biopharmaceuticals

Connect Biopharmaceuticals is a China-based clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our drug discovery technology platform is built on the biology of T cell functions, which identifies molecules that target clinically-validated disease pathways.


We are currently conducting multiple clinical studies on two drug candidates that have the potential to treat a broad range of severe chronic inflammatory diseases. The first such lead drug candidate CBP-307, currently in two phase 2 clinical studies in ulcerative colitis and Crohn's disease, is an orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor -GPCR) modulator for the treatment of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  The drug candidate has been studied in two phase 1 studies involving 74 healthy volunteers and has demonstrated excellent tolerability, potent T cell modulation activity and optimal pharmacokinetic properties. The other drug candidate is CBP-201, a highly-potent antibody that targets IL-4Rα and blocks a central pathway in allergic inflammation, is currently in a phase 1 clinical study and is expected to be studied in atopic dermatitis patients commencing in Q1, 2019.  

 

Media Contact:

Dr. Chris Song

csong@connectpharm.com

 


TEL/FAX: 0512-53577866

E-MAIL: swlu@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd. 苏ICP备17002143号

Technical support: Epower